部門紹介

研究業績

最終更新日 : 2017年10月4日

目次

  1. 原著論文
  2. 解説・総説や教科書など

原著論文

2017年

Fuse, J. M., Okada, K., Oh-hara, T., Ogura, H., Fujita, N. and Katayama, R.
Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers. Mol. Cancer Ther., in press (2017)
Takemoto, A., Miyata, K. and Fujita, N.
Platelet-activating factor podoplanin: from discovery to drug development.
Cancer and metastasis reviews, 36, 225-234 (2017)
Ogura, H., Nagatake-Kobayashi, Y., Adachi, J., Tomonaga, T., Fujita, N. and Katayama, R.
TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.
Sci. Rep., 7, 5519 (2017)
Miyata, K., Takemoto, A., Okumura, S., Nishio, M. and Fujita, N.
Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation.
Sci. Rep., 7, 4059 (2017)
Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R.
Brigatinib overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nature Commun, 8: 14768 (2017).
Takemoto, A., Okitaka, M., Takagi, S., Takami, M., Sato, S., Nishio, M., Okumura, S., Fujita, N.
A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis. Sci Reports, 7: 42186 (2017).
Takeuchi, S., Fukuda, K., Yamada, T., Arai, S., Takagi, S., Ishii, G., Ochiai, A., Iwakiri, S., Itoi, K., Uehara,H., Nishihara, H., Fujita, N., Yano, S.
Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and contact inhibition. Cancer Sci, In press (2017).
Tanaka, N., Mashima, T., Mizutani, A., Sato, A., Aoyama, A., Gong, B., Yoshida, H., Muramatsu,Y., Nakata, K., Matsuura, M., Katayama, R., Nagayama, S., Fujita, N., Sugimoto, Y., Seimiya H.
APC mutations as a predictive biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.Mol Cancer Ther. 2017 Apr;16(4):752-762.
R. Katayama.
Therapeutic strategies and mechanisms of drug resistance in Anaplastic Lymphoma Kinase (ALK)-rearranged lung cancer.
Pharmacol. Ther., 117, 1-8 (2017)

このページのTOPへ

2016年

Katayama, R., Sakashita, T., Yanagitani, N., Ninomiya, H., Horiike, A., Friboulet, L., Gainor, J. F., Motoi, N., Dobashi, A., Sakata, S., Tambo, Y., Kitazono, S., Sato, S., Koike, S., Iafrate, A. J., Mino-Kenudson, M., Ishikawa, Y., Shaw, A. T., Engleman, J. A., Takeuchi, K., Nishio, M., Fujita, N.
P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine, 3, 54-66 (2016)
Shaw, A. T., Friboulet, L., Leshchiner, I., Gainor, J. F., Berggvist, S., Brooun, A., Burke, B. J., Deng, Y. L., Liu, W., Dardaei, L., Frias, R. L., Schultz, K. R., Logan, J., James, L. P., Smeal, T., Timofeevski, S., Katayama, R., Iafrate, A. J., Le, L., McTigue, M., Getz, G., Johnson, T. W., Engelman, J. A.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med, 374: 54-61 (2016)
Sekiguchi, T., Takemoto, A., Takagi, S., Takatori, K., Sato, S., Takami, M., Fujita, N.
Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget, 7, 3934-3946 (2016)
J. F. Gainor, L. Dardaei, S. Yoda, L. Friboulet, I. Leshchiner, R. Katayama, I. Dagogo-Jack, S. Gadgeel, K. Schultz, M. Singh, E. Chin, M. Parks, D. Lee, R. H. DiCecca, E. Lockerman, T. Huynh, J. Logan, L. L. Ritterhouse, L. P. Le, A. Muniappan, S. Digumarthy, C. Channick, C. Keyes, G. Getz, D. Dias-Santagata, R. S. Heist, J. Lennerz, L. V. Sequist, C. H. Benes, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman and A. T. Shaw.
Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer.
Cancer Discov., 6, 1118-1133 (2016)

このページのTOPへ

2015年

Katayama, R., Kobayashi, Y., Friboulet, L., Lockerman, E.L., Koike, S., Shaw, A.T., Engelman, J.A., Fujita, N.
Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer.
Clin Cancer Res, 21, 166-174 (2015)
Hu, D., Gur, M., Zhou, Z., Gamper, A., Hung, M. C., Fujita, N., Lan, L., Bahar, I., Wan, Y.
Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis.
Nat Commun, 6, 8419 (2015)
Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., Howe, E., Fulton, L. E., Mulvey, H. E., Bernardo, L. A., Mohamoud, F., Miyoshi, N., VanderLaan, P. A., Costa, D. B., Janne, P. A., Borger, D. R., Ramaswamy, S., Shioda, T., Iafrate, A. J., Getz, G., Rudin, C. M., Mino-Kenudson, M., Engelman, J. A.
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun, 6, 6377 (2015)
Yamada, T., Amann, J. M., Fukuda, K., Takeuchi, S., Fujita, N., Uehara, H., Iwakiri, S., Itoi, K., Shilo, K., Yano, S., Carbone, D. P.
Akt kinase-interacting protein Aki1 signals through CREB to drive diffuse malignant mesothelioma. Cancer Res, 75, 4188-4197 (2015)
Zou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., Tang, R. W., Wang, H., Tsaparikos, K., Wang, J., Timofeevski, S., Katayama, R., Dinh, D. M., Lam, H., Lam, J. L., Yamazaki, S., Hu, W., Patel, B., Bezwada, D., Frias, R. L., Lifshits, E., Mahmood, S., Gainor, J. F., Affolter, T., Lappin, P. B., Gukasyan, H., Lee, N., Deng, S., Jain, R. K., Johnson, T. W., Shaw, A. T., Fantin, V. R., Smeal, T.
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell, 28, 70-81 (2015)

このページのTOPへ

2014年

Aoyama, A., Katayama, R., Oh-hara, T., Sato, S., Okuno, Y., Fujita, N.
Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Mol Cancer Ther, 13, 2978-2990 (2014)
Chowdhury, M.M., Danoy, M., Rahman, F., Shinohara, M., Kaneda, S., Shiba, K., Fujita, N., Fujii, T., Sakai, Y.
Adhesion of pancreatic cancer cells in a liver-microvasculature mimicking coculture correlates with their propensity to form liver-specific metastasis in vivo.
Biomed Res Int, 2014, 241571 (2014)
Friboulet, L., Li, N., Katayama, R., Lee, C.C., Gainor, J.F., Crystal, A.S., Michellys, P.Y., Awad, M.M., Yanagitani, N., Kim, S., Pferdekamper, A.C., Li, J., Kasibhatla, S., Sun, F., Sun, X., Hua, S., McNamara, P., Mahmood, S., Lockerman, E.L., Fujita, N., Nishio, M., Harris, J.L., Shaw, A.T., Engelman, J.A.
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Cancer Discov, 4, 662-673 (2014)
Katayama, R., Friboulet, L., Koike, S., Lockerman, E.L., Khan, T.M., Gainor, J.F., Iafrate, A.J., Takeuchi, K., Taiji, M., Okuno, Y., Fujita, N., Engelman, J.A., Shaw, A.T.
Two novel ALK mutations mediate acquired resistance to the next-generation AKL inhibitor alectinib.
Clin Cancer Res, 20, 5686-5696 (2014)
Miyata, K., Takagi, S., Sato, S., Morioka, H., Shiba, K., Minamisawa, T., Takami, M., Fujita, N.
Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment.
Cancer Med, 3, 1595-1604 (2014)
Ohtsubo, K., Yamada, T., Zhao, L., Jin, T.F., Takeuchi, S., Mouri, H., Yamashita, K., Yasumoto, K., Fujita, N., Kitagawa, H., Ohta, T., Ikeda, H., Yano, S.
Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer.
Pancreas, 43, 1093-1100 (2014)
Pond, A.L., Nedele, C., Wang, W.H., Wang, X., Walther, C., Jaeger, C., Bradley, K.S., Du, H., Fujita, N., Hockerman, G.H., Hannon, K.M.
The mERG1a channel modulates skeletal muscle MuRF1, but not MAFbx, expression.
Muscle Nerve, 49, 378-388 (2014)
Takagi, S., Oh-Hara, T., Sato, S., Gong, B., Takami, M., Fujita, N.
Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis.
Int J Cancer, 134, 2605-2614 (2014)
Takagi, S., Takemoto, A., Takami, M., Oh-Hara, T., Fujita, N.
Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis.
Cancer Sci, 105, 983-988 (2014)

このページのTOPへ

2013年

Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-Hara, T., Song, Y., Engelman, J.A., Fujita, N.
Cytotoxic activity of Tivanitib (ARQ 197) is not due solely to c-MET inhibition.
Cancer Res, 73, 3087-3096 (2013)
Takagi, S., Sato, S., Oh-Hara, T., Takagi, M., Koike, S., Mishima, Y., Hatake, K., Fujita, N.
Platelets promote tumor growth and metastasis via direct interaction between Aggrus/Podoplanin and CLEC-2.
PLoS One, 8, e73609 (2013)
Yamada, T., Takeuchi, S., Fujita, N., Nakamura, A., Wang, W., Li, Q., Oda, M., Mitsudomi, T., Yatabe, Y., Sekido, Y., Yoshida, J., Higashiyama, M., Noguchi, M., Uehara, H., Nishioka, Y., Sone, S., Yano, S.
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
Oncogene, 32, 4427-4435 (2013)

このページのTOPへ

2012年

Fujita, N., Takagi, S.
The impact of Aggrus/podoplanin on platelet aggregation and tumor metastasis.
J Biochem, 152, 407-413 (2012)
Hahne, J.C., Honig, A., Meyer, S.R., Gambaryan, S., Walter, U., Wischhusen, J., Haussler, S.F., Segerer, S.E., Fujita, N., Dietl, J., Engel, J.B.
Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Oncol Rep, 28, 2023-2028 (2012)
Mohanty, A.R., Kan, Q., Srivastava, S., Uranbileg, B., Arakawa-Takeuchi, S., Fujita, N., Okayama, H.
Successive phosphorylation of p27Kip1 protein at serine-10 and C-terminus crucially controls its cotency to inactivate cdk2.
J Biol Chem, 287, 21757-21764 (2012)

このページのTOPへ

2011年

Ehata, S., Johansson, E., Katayama, R., Koike, S., Watanabe, A., Hoshino, Y., Katsuno, Y., Komuro, A., Koinuma, D., Kano, M.R., Yashiro, M., Hirakawa, K., Aburatani, H., Fujita, N., Miyazono, K.
Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells.
Oncogene, 30, 1693-1705 (2011)
Konishi, S., Yasuchika, K., Ishii, T., Fukumitsu, K., Kamo, N., Fujita, N., Ikai, I., Uemoto, S.
A transmembrane glycoprotein, gp38, is a novel marker for immature hepatic progenitor cells in fetal mouse livers.
In Vitro Cell Dev Biol Anim, 47, 45-53 (2011)
Morishita, D., Takami, M., Yoshikawa, S., Katayama, R., Sato, S., Kukimoto-Niino, M., Umehara, T., Shirouzu, M., Sekimizu, K., Yokoyama, S., Fujita, N.
Cell-permeable carboxyl-terminal p27Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
J Biol Chem, 286, 2681-2688 (2011)
Nakazawa, Y., Arai, H., Fujita, N.
The novel metastasis promoter Merm1/Wbscr22 enhances tumor cell survival in the vasculature by suppressing Zac1/p53-dependent apoptosis.
Cancer Res, 71, 1146-1155 (2011)
Nakazawa, Y., Takagi, S., Sato, S., Oh-Hara, T., Koike, S., Takami, M., Arai, H., Fujita, N.
Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies.
Cancer Sci, 102, 2051-2057 (2011)

このページのTOPへ

2010年

Katayama, R., Ishioka, T., Takada, S., Takada, R., Fujita, N., Tsuruo, T., Naito, M.
Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L.
J Cell Sci, 123, 23-28 (2010)
Misawa, A., Katayama, R., Koike, S., Tomida, A., Watanabe, T., Fujita, N.
AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells.
Oncol Res, 19, 23-33 (2010)
Nakamura, A., Naito, M., Arai, H., Fujita, N.
Mitotic phosphorylation of Aki1 at Ser208 by cyclin B1-Cdk1 complex.
Biochem Biophys Res Commun, 393, 872-876 (2010)
Péterfy, M., Harris, T.E., Fujita, N., Reue, K.
Insulin-stimulated interaction with 14-3-3 promotes cytoplasmic localization of lipin-1 in adipocytes.
J Biol Chem, 285, 3857-3864 (2010)

このページのTOPへ

2009年

Demers, M.J., Thibodeau, S., Noel, D., Fujita, N., Tsuruo, T., Gauthier, R., Arguin, M., Vachon, P.H.
Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1.
J Cell Biochem, 107, 639-654 (2009)
Katayama, R., Koike, S., Sato, S., Sugimoto, Y., Tsuruo, T., Fujita, N.
Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
Cancer Sci, 100, 2060-2068 (2009)
Nakamura, A., Arai, H., Fujita, N.
Centrosomal Aki1 and cohesin function in separase-regulated centriole disengagement.
J Cell Biol, 187, 607-614 (2009)
Tanaka, H., Hoshikawa, Y., Oh-hara, T., Koike, S., Naito, M., Noda, T., Arai, H., Tsuruo, T., Fujita, N.
PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-κB activation.
Mol Cancer Res, 7, 557-569 (2009)

このページのTOPへ